

# Global Generic Anti-cancer Injectables Market Research Report 2023

<https://marketpublishers.com/r/G5CE6A8F2109EN.html>

Date: December 2023

Pages: 86

Price: US\$ 2,900.00 (Single User License)

ID: G5CE6A8F2109EN

## Abstracts

According to QYResearch's new survey, global Generic Anti-cancer Injectables market is projected to reach US\$ million in 2029, increasing from US\$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Generic Anti-cancer Injectables market research.

Key companies engaged in the Generic Anti-cancer Injectables industry include Teva, Viartis, Biocon, Amgen, Sandoz (Novartis), Pfizer, Qilu Pharmaceutical, Jiangsu Hansoh and CTTQ, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Generic Anti-cancer Injectables were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Generic Anti-cancer Injectables market and estimated to attract more attentions from industry insiders and investors.

## Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Generic Anti-cancer Injectables market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

## By Company

Teva

Viartis

Biocon

Amgen

Sandoz (Novartis)

Pfizer

Qilu Pharmaceutical

Jiangsu Hansoh

CTTQ

Jiangsu Hengrui

CSPC

Innovent Biologics

### Segment by Type

Bevacizuma

Rituximab

Herceptin

Paclitaxel

Others

### Segment by Application

Hospital

Retail

## By Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

The Generic Anti-cancer Injectables report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Generic Anti-cancer Injectables Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 Bevacizuma

1.2.3 Rituximab

1.2.4 Herceptin

1.2.5 Paclitaxel

1.2.6 Others

1.3 Market by Application

1.3.1 Global Generic Anti-cancer Injectables Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Retail

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

### 2 GLOBAL GROWTH TRENDS

2.1 Global Generic Anti-cancer Injectables Market Perspective (2018-2029)

2.2 Generic Anti-cancer Injectables Growth Trends by Region

2.2.1 Global Generic Anti-cancer Injectables Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Generic Anti-cancer Injectables Historic Market Size by Region (2018-2023)

2.2.3 Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029)

2.3 Generic Anti-cancer Injectables Market Dynamics

2.3.1 Generic Anti-cancer Injectables Industry Trends

2.3.2 Generic Anti-cancer Injectables Market Drivers

2.3.3 Generic Anti-cancer Injectables Market Challenges

2.3.4 Generic Anti-cancer Injectables Market Restraints

### 3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Generic Anti-cancer Injectables Players by Revenue

- 3.1.1 Global Top Generic Anti-cancer Injectables Players by Revenue (2018-2023)
- 3.1.2 Global Generic Anti-cancer Injectables Revenue Market Share by Players (2018-2023)
- 3.2 Global Generic Anti-cancer Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Generic Anti-cancer Injectables Revenue
- 3.4 Global Generic Anti-cancer Injectables Market Concentration Ratio
  - 3.4.1 Global Generic Anti-cancer Injectables Market Concentration Ratio (CR5 and HHI)
  - 3.4.2 Global Top 10 and Top 5 Companies by Generic Anti-cancer Injectables Revenue in 2022
- 3.5 Generic Anti-cancer Injectables Key Players Head office and Area Served
- 3.6 Key Players Generic Anti-cancer Injectables Product Solution and Service
- 3.7 Date of Enter into Generic Anti-cancer Injectables Market
- 3.8 Mergers & Acquisitions, Expansion Plans

#### **4 GENERIC ANTI-CANCER INJECTABLES BREAKDOWN DATA BY TYPE**

- 4.1 Global Generic Anti-cancer Injectables Historic Market Size by Type (2018-2023)
- 4.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029)

#### **5 GENERIC ANTI-CANCER INJECTABLES BREAKDOWN DATA BY APPLICATION**

- 5.1 Global Generic Anti-cancer Injectables Historic Market Size by Application (2018-2023)
- 5.2 Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029)

#### **6 NORTH AMERICA**

- 6.1 North America Generic Anti-cancer Injectables Market Size (2018-2029)
- 6.2 North America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 6.3 North America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
- 6.4 North America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
- 6.5 United States
- 6.6 Canada

## **7 EUROPE**

- 7.1 Europe Generic Anti-cancer Injectables Market Size (2018-2029)
- 7.2 Europe Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 Europe Generic Anti-cancer Injectables Market Size by Country (2018-2023)
- 7.4 Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029)
- 7.5 Germany
- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

## **8 ASIA-PACIFIC**

- 8.1 Asia-Pacific Generic Anti-cancer Injectables Market Size (2018-2029)
- 8.2 Asia-Pacific Generic Anti-cancer Injectables Market Growth Rate by Region: 2018 VS 2022 VS 2029
- 8.3 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2018-2023)
- 8.4 Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2024-2029)
- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

## **9 LATIN AMERICA**

- 9.1 Latin America Generic Anti-cancer Injectables Market Size (2018-2029)
- 9.2 Latin America Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2023)
- 9.4 Latin America Generic Anti-cancer Injectables Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

## **10 MIDDLE EAST & AFRICA**



- 10.1 Middle East & Africa Generic Anti-cancer Injectables Market Size (2018-2029)
- 10.2 Middle East & Africa Generic Anti-cancer Injectables Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2018-2023)
- 10.4 Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

## **11 KEY PLAYERS PROFILES**

### 11.1 Teva

- 11.1.1 Teva Company Detail
- 11.1.2 Teva Business Overview
- 11.1.3 Teva Generic Anti-cancer Injectables Introduction
- 11.1.4 Teva Revenue in Generic Anti-cancer Injectables Business (2018-2023)
- 11.1.5 Teva Recent Development

### 11.2 Viatris

- 11.2.1 Viatris Company Detail
- 11.2.2 Viatris Business Overview
- 11.2.3 Viatris Generic Anti-cancer Injectables Introduction
- 11.2.4 Viatris Revenue in Generic Anti-cancer Injectables Business (2018-2023)
- 11.2.5 Viatris Recent Development

### 11.3 Biocon

- 11.3.1 Biocon Company Detail
- 11.3.2 Biocon Business Overview
- 11.3.3 Biocon Generic Anti-cancer Injectables Introduction
- 11.3.4 Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2023)
- 11.3.5 Biocon Recent Development

### 11.4 Amgen

- 11.4.1 Amgen Company Detail
- 11.4.2 Amgen Business Overview
- 11.4.3 Amgen Generic Anti-cancer Injectables Introduction
- 11.4.4 Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2023)
- 11.4.5 Amgen Recent Development

### 11.5 Sandoz (Novartis)

- 11.5.1 Sandoz (Novartis) Company Detail
- 11.5.2 Sandoz (Novartis) Business Overview
- 11.5.3 Sandoz (Novartis) Generic Anti-cancer Injectables Introduction
- 11.5.4 Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2023)
- 11.5.5 Sandoz (Novartis) Recent Development
- 11.6 Pfizer
  - 11.6.1 Pfizer Company Detail
  - 11.6.2 Pfizer Business Overview
  - 11.6.3 Pfizer Generic Anti-cancer Injectables Introduction
  - 11.6.4 Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2023)
  - 11.6.5 Pfizer Recent Development
- 11.7 Qilu Pharmaceutical
  - 11.7.1 Qilu Pharmaceutical Company Detail
  - 11.7.2 Qilu Pharmaceutical Business Overview
  - 11.7.3 Qilu Pharmaceutical Generic Anti-cancer Injectables Introduction
  - 11.7.4 Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2023)
  - 11.7.5 Qilu Pharmaceutical Recent Development
- 11.8 Jiangsu Hansoh
  - 11.8.1 Jiangsu Hansoh Company Detail
  - 11.8.2 Jiangsu Hansoh Business Overview
  - 11.8.3 Jiangsu Hansoh Generic Anti-cancer Injectables Introduction
  - 11.8.4 Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2023)
  - 11.8.5 Jiangsu Hansoh Recent Development
- 11.9 CTTQ
  - 11.9.1 CTTQ Company Detail
  - 11.9.2 CTTQ Business Overview
  - 11.9.3 CTTQ Generic Anti-cancer Injectables Introduction
  - 11.9.4 CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2023)
  - 11.9.5 CTTQ Recent Development
- 11.10 Jiangsu Hengrui
  - 11.10.1 Jiangsu Hengrui Company Detail
  - 11.10.2 Jiangsu Hengrui Business Overview
  - 11.10.3 Jiangsu Hengrui Generic Anti-cancer Injectables Introduction
  - 11.10.4 Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2023)
  - 11.10.5 Jiangsu Hengrui Recent Development

## 11.11 CSPC

11.11.1 CSPC Company Detail

11.11.2 CSPC Business Overview

11.11.3 CSPC Generic Anti-cancer Injectables Introduction

11.11.4 CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2023)

11.11.5 CSPC Recent Development

## 11.12 Innovent Biologics

11.12.1 Innovent Biologics Company Detail

11.12.2 Innovent Biologics Business Overview

11.12.3 Innovent Biologics Generic Anti-cancer Injectables Introduction

11.12.4 Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2023)

11.12.5 Innovent Biologics Recent Development

## 12 ANALYST'S VIEWPOINTS/CONCLUSIONS

## 13 APPENDIX

### 13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

### 13.2 Disclaimer

### 13.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Global Generic Anti-cancer Injectables Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Bevacizuma

Table 3. Key Players of Rituximab

Table 4. Key Players of Herceptin

Table 5. Key Players of Paclitaxel

Table 6. Key Players of Others

Table 7. Global Generic Anti-cancer Injectables Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 8. Global Generic Anti-cancer Injectables Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 9. Global Generic Anti-cancer Injectables Market Size by Region (2018-2023) & (US\$ Million)

Table 10. Global Generic Anti-cancer Injectables Market Share by Region (2018-2023)

Table 11. Global Generic Anti-cancer Injectables Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 12. Global Generic Anti-cancer Injectables Market Share by Region (2024-2029)

Table 13. Generic Anti-cancer Injectables Market Trends

Table 14. Generic Anti-cancer Injectables Market Drivers

Table 15. Generic Anti-cancer Injectables Market Challenges

Table 16. Generic Anti-cancer Injectables Market Restraints

Table 17. Global Generic Anti-cancer Injectables Revenue by Players (2018-2023) & (US\$ Million)

Table 18. Global Generic Anti-cancer Injectables Market Share by Players (2018-2023)

Table 19. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)

Table 20. Ranking of Global Top Generic Anti-cancer Injectables Companies by Revenue (US\$ Million) in 2022

Table 21. Global 5 Largest Players Market Share by Generic Anti-cancer Injectables Revenue (CR5 and HHI) & (2018-2023)

Table 22. Key Players Headquarters and Area Served

Table 23. Key Players Generic Anti-cancer Injectables Product Solution and Service

Table 24. Date of Enter into Generic Anti-cancer Injectables Market

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Generic Anti-cancer Injectables Market Size by Type (2018-2023) & (US\$ Million)

Table 27. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2018-2023)

Table 28. Global Generic Anti-cancer Injectables Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 29. Global Generic Anti-cancer Injectables Revenue Market Share by Type (2024-2029)

Table 30. Global Generic Anti-cancer Injectables Market Size by Application (2018-2023) & (US\$ Million)

Table 31. Global Generic Anti-cancer Injectables Revenue Market Share by Application (2018-2023)

Table 32. Global Generic Anti-cancer Injectables Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 33. Global Generic Anti-cancer Injectables Revenue Market Share by Application (2024-2029)

Table 34. North America Generic Anti-cancer Injectables Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 35. North America Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US\$ Million)

Table 36. North America Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US\$ Million)

Table 37. Europe Generic Anti-cancer Injectables Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 38. Europe Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US\$ Million)

Table 39. Europe Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US\$ Million)

Table 40. Asia-Pacific Generic Anti-cancer Injectables Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 41. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2018-2023) & (US\$ Million)

Table 42. Asia-Pacific Generic Anti-cancer Injectables Market Size by Region (2024-2029) & (US\$ Million)

Table 43. Latin America Generic Anti-cancer Injectables Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 44. Latin America Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US\$ Million)

Table 45. Latin America Generic Anti-cancer Injectables Market Size by Country

(2024-2029) & (US\$ Million)

Table 46. Middle East & Africa Generic Anti-cancer Injectables Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 47. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2018-2023) & (US\$ Million)

Table 48. Middle East & Africa Generic Anti-cancer Injectables Market Size by Country (2024-2029) & (US\$ Million)

Table 49. Teva Company Detail

Table 50. Teva Business Overview

Table 51. Teva Generic Anti-cancer Injectables Product

Table 52. Teva Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 53. Teva Recent Development

Table 54. Viartis Company Detail

Table 55. Viartis Business Overview

Table 56. Viartis Generic Anti-cancer Injectables Product

Table 57. Viartis Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 58. Viartis Recent Development

Table 59. Biocon Company Detail

Table 60. Biocon Business Overview

Table 61. Biocon Generic Anti-cancer Injectables Product

Table 62. Biocon Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 63. Biocon Recent Development

Table 64. Amgen Company Detail

Table 65. Amgen Business Overview

Table 66. Amgen Generic Anti-cancer Injectables Product

Table 67. Amgen Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 68. Amgen Recent Development

Table 69. Sandoz (Novartis) Company Detail

Table 70. Sandoz (Novartis) Business Overview

Table 71. Sandoz (Novartis) Generic Anti-cancer Injectables Product

Table 72. Sandoz (Novartis) Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 73. Sandoz (Novartis) Recent Development

Table 74. Pfizer Company Detail

Table 75. Pfizer Business Overview

- Table 76. Pfizer Generic Anti-cancer Injectables Product
- Table 77. Pfizer Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 78. Pfizer Recent Development
- Table 79. Qilu Pharmaceutical Company Detail
- Table 80. Qilu Pharmaceutical Business Overview
- Table 81. Qilu Pharmaceutical Generic Anti-cancer Injectables Product
- Table 82. Qilu Pharmaceutical Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 83. Qilu Pharmaceutical Recent Development
- Table 84. Jiangsu Hansoh Company Detail
- Table 85. Jiangsu Hansoh Business Overview
- Table 86. Jiangsu Hansoh Generic Anti-cancer Injectables Product
- Table 87. Jiangsu Hansoh Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 88. Jiangsu Hansoh Recent Development
- Table 89. CTTQ Company Detail
- Table 90. CTTQ Business Overview
- Table 91. CTTQ Generic Anti-cancer Injectables Product
- Table 92. CTTQ Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 93. CTTQ Recent Development
- Table 94. Jiangsu Hengrui Company Detail
- Table 95. Jiangsu Hengrui Business Overview
- Table 96. Jiangsu Hengrui Generic Anti-cancer Injectables Product
- Table 97. Jiangsu Hengrui Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 98. Jiangsu Hengrui Recent Development
- Table 99. CSPC Company Detail
- Table 100. CSPC Business Overview
- Table 101. CSPC Generic Anti-cancer Injectables Product
- Table 102. CSPC Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)
- Table 103. CSPC Recent Development
- Table 104. Innovent Biologics Company Detail
- Table 105. Innovent Biologics Business Overview
- Table 106. Innovent Biologics Generic Anti-cancer Injectables Product
- Table 107. Innovent Biologics Revenue in Generic Anti-cancer Injectables Business (2018-2023) & (US\$ Million)

Table 108. Innovent Biologics Recent Development

Table 109. Research Programs/Design for This Report

Table 110. Key Data Information from Secondary Sources

Table 111. Key Data Information from Primary Sources



## List Of Figures

### LIST OF FIGURES

- Figure 1. Global Generic Anti-cancer Injectables Market Size Comparison by Type (2023-2029) & (US\$ Million)
- Figure 2. Global Generic Anti-cancer Injectables Market Share by Type: 2022 VS 2029
- Figure 3. Bevacizuma Features
- Figure 4. Rituximab Features
- Figure 5. Herceptin Features
- Figure 6. Paclitaxel Features
- Figure 7. Others Features
- Figure 8. Global Generic Anti-cancer Injectables Market Size Comparison by Application (2023-2029) & (US\$ Million)
- Figure 9. Global Generic Anti-cancer Injectables Market Share by Application: 2022 VS 2029
- Figure 10. Hospital Case Studies
- Figure 11. Retail Case Studies
- Figure 12. Generic Anti-cancer Injectables Report Years Considered
- Figure 13. Global Generic Anti-cancer Injectables Market Size (US\$ Million), Year-over-Year: 2018-2029
- Figure 14. Global Generic Anti-cancer Injectables Market Size, (US\$ Million), 2018 VS 2022 VS 2029
- Figure 15. Global Generic Anti-cancer Injectables Market Share by Region: 2022 VS 2029
- Figure 16. Global Generic Anti-cancer Injectables Market Share by Players in 2022
- Figure 17. Global Top Generic Anti-cancer Injectables Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Anti-cancer Injectables as of 2022)
- Figure 18. The Top 10 and 5 Players Market Share by Generic Anti-cancer Injectables Revenue in 2022
- Figure 19. North America Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 20. North America Generic Anti-cancer Injectables Market Share by Country (2018-2029)
- Figure 21. United States Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)
- Figure 22. Canada Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 23. Europe Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Generic Anti-cancer Injectables Market Share by Country (2018-2029)

Figure 25. Germany Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 26. France Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. U.K. Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. Italy Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Russia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Nordic Countries Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Asia-Pacific Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Generic Anti-cancer Injectables Market Share by Region (2018-2029)

Figure 33. China Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 34. Japan Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. South Korea Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. Southeast Asia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. India Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. Australia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Latin America Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Generic Anti-cancer Injectables Market Share by Country (2018-2029)

Figure 41. Mexico Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 42. Brazil Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029)

& (US\$ Million)

Figure 43. Middle East & Africa Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Generic Anti-cancer Injectables Market Share by Country (2018-2029)

Figure 45. Turkey Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 46. Saudi Arabia Generic Anti-cancer Injectables Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Teva Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 48. Viartis Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 49. Biocon Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 50. Amgen Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 51. Sandoz (Novartis) Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 52. Pfizer Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 53. Qilu Pharmaceutical Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 54. Jiangsu Hansoh Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 55. CTTQ Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 56. Jiangsu Hengrui Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 57. CSPC Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 58. Innovent Biologics Revenue Growth Rate in Generic Anti-cancer Injectables Business (2018-2023)

Figure 59. Bottom-up and Top-down Approaches for This Report

Figure 60. Data Triangulation

Figure 61. Key Executives Interviewed

## I would like to order

Product name: Global Generic Anti-cancer Injectables Market Research Report 2023

Product link: <https://marketpublishers.com/r/G5CE6A8F2109EN.html>

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G5CE6A8F2109EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970